

VICTOZA - (6mg/ml; Solution, Subcutaneous)

| | | | |
|------------------------------|--|-----------------------------|---------------------|
| Generic Name | LIRAGLUTIDE RECOMBINANT | Innovator | Novo Nordisk |
| Dosage | 6mg/ml; Solution, Subcutaneous | Branded US Sales | More Than \$1000 mn |
| Probable FTF | Less Than 5 | Known Para IV Filers | More Than 5 |
| Other ANDA developers | More Than 5 | Tentative Approvals | None |
| Final Approvals | Less Than 5 | Generic Launches | Less Than 5 |
| Indication | VICTOZA is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated: • as an adjunct to diet and exercise to improve glycemic control in patients 10 years and older with type 2 diabetes mellitus. • to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease | | |
| Complexities | Yes | | |

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.